Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Articles|August 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 8
- Volume 7
- Issue 8
Koplan Named New Head of CDC
WASHINGTON--President Clinton has appointed Dr. Jeffrey P. Koplan, an epidemiologist, as director of the Centers for Disease Control and Prevention, replacing Dr. David Satcher, who left last February to become Surgeon General. Dr. Koplan was with the CDC for most of his career, starting in 1972, until leaving 4 years ago to join Prudential Healthcare as president of its Center for Health Care Research.
Advertisement
WASHINGTON--President Clinton has appointed Dr. Jeffrey P. Koplan, an epidemiologist, as director of the Centers for Disease Control and Prevention, replacing Dr. David Satcher, who left last February to become Surgeon General. Dr. Koplan was with the CDC for most of his career, starting in 1972, until leaving 4 years ago to join Prudential Healthcare as president of its Center for Health Care Research.
Articles in this issue
about 28 years ago
Taxol, Gemzar, Other Therapies Studied in Metastatic Bladder Cancerabout 28 years ago
Medicare+Choice Opens Certificationabout 28 years ago
Consumer Advocates Win a Voice in NCI Programsabout 28 years ago
Paclitaxel Shows Antiangiogenesis Effects in Mouse Modelabout 28 years ago
Henney Nominated for FDA Commissionerabout 28 years ago
FDA Approves ImageChecker Computer Systemabout 28 years ago
Pittsburgh Seeks Breast Cancer Patients for Study on Copingabout 28 years ago
Octreotide Imaging Improves Staging of Hodgkin’s Diseaseabout 28 years ago
Tobacco Contributions Are Linked to Votes Against Tobacco Billabout 28 years ago
Kaposi’s Sarcoma, Cervical Dysplasia Both Improve With Anti-HIV TherapyAdvertisement
Related to this article
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
5